BioSpace News Archive

Global Blood Therapeutics, Inc. announced that on March 1, 2021, the compensation committee of GBT’s board of directors granted 14 new employees options to purchase an aggregate of 11,525 shares of the company’s common stock with a per share exercise price of $44.48 and restricted stock units for an aggregate of 43,800 shares of the company’s common stock.

Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg, M.D., Chief Executive Officer, will participate in a fireside chat at the 33rd Annual Roth Conference on Monday, March 15 at 2:00 p.m. ET.

BrainsWay Ltd., a global leader in the advanced non-invasive treatment of brain disorders, announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer 31st Annual Healthcare Conference taking place on March 16-18, 2021.

AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of an aggregate of 7,858,548 shares of common stock

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update following recent interactions with the U.S. Food and Drug Administration (FDA) regarding the development of once-daily DCCR (diazoxide choline) extended release tablets for the treatment of Prader-Willi Syndrome (PWS).

Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that it will present its request for an ICD-10 code at a Center for Medicare and Medicaid Services (CMS) meeting on March 9 th .

The Lundquist Institute and The Bill & Melinda Gates Medical Research Institute executed a license agreement for TLI intellectual property covering a synthetic lung surfactant formulation to be developed for respiratory distress syndrome for premature infants in Low- and Middle-Income countries.

Cleave Therapeutics, Inc. (“Cleave”), a clinical-stage biopharmaceutical company focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response and other cellular stress pathways for therapeutic use in cancer, and CASI Pharmaceuticals, Inc (NASDAQ: CASI)

New Neonatal Study Adds to Body of Clinical Evidence Demonstrating Masimo SET® Pulse Oximetry’s Unique Ability to Improve Care

Polyimide is a thermoset plastic used in a number of medical applications for tubing purposes. Polyimide has excellent thermal stability, chemical resistance, and tensile strength.